Closed · PA-07-299 · CFDA 93.393 · Discretionary
Epigenetic Approaches in Cancer Epidemiology (R21)
Federal grant opportunity posted by National Institutes of Health, cataloged on Grants.gov.
- up to $200K
- Award range
- Closed
- Status
- -
- Close date
- -
- Expected awards
The verdict
Epigenetic Approaches in Cancer Epidemiology (R21) is a closed discretionary listing from National Institutes of Health that offered Up to $200,000. Future funding cycles may be published under the same CFDA number. PlainGrants indexes 12,419 other opportunities from National Institutes of Health.
- up to $200K
- award range
- Closed
- application status
- 93.393
- CFDA program
- 12,419
- other opportunities from National Institutes of Health
Archived opportunity record
Epigenetic Approaches in Cancer Epidemiology is closed. The parent program page for CFDA 93.393 is the reliable place to catch re-announcements. National Institutes of Health still indexes 12,419 other opportunities here.
According to Grants.gov (extract vintage 2026-08-10), this record reflects the officially published listing. See methodology.
Deadline tracker
Application window closed
This listing is no longer accepting applications
Instrument
Grant
Description
-Purpose. The purpose of this concept is to stimulate population-based epidemiology research on the roles of DNA methylation markers in cancer. -Mechanism of Support. This Funding Opportunity Announcement (FOA) will utilize the NIH developmental/exploratory (R21) grant mechanism and it runs in parallel with an FOA of identical scientific scope, PA-07-298, which solicits applications under the NIH research project (R01) grant mechanism. -Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications. Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the mechanism numbers, quality, duration, and costs of the applications received.
Market-open applicant set · includes for-profit door
The eligibility set for Epigenetic Approaches in Cancer Epidemiology includes a for-profit door among 7 printed types (Public / state-controlled institutions of higher education; Nonprofits with 501(c)(3) status (other than IHEs); Nonprofits without 501(c)(3) status (other than IHEs); Private institutions of higher education; +3 more). Competitive traffic can include commercial applicants alongside other listed classes. The extract does not mark applicant cost-sharing as required. Instrument: Grant. Funding-activity codes span Education · Health (ED;HL). Only 164 other National Institutes of Health listings share this exact eligibility-code string (1% of 12,420).
- Code 06
- Public / state-controlled institutions of higher education
- Code 12
- Nonprofits with 501(c)(3) status (other than IHEs)
- Code 13
- Nonprofits without 501(c)(3) status (other than IHEs)
- Code 20
- Private institutions of higher education
- Code 22
- For-profit organizations other than small businesses
- Code 23
- Small businesses
- Code 25
- Others (see official listing text)
Codes are Grants.gov eligibility category values from the extract vintage 2026-08-10. Confirm the full eligibility statement on the official listing or the Grants.gov eligibility reference.
Official Listing on Grants.gov
View full details, application forms, and submission instructions.
Parent Grant Program
Cancer Research Grants
National Institutes of Health
Agency Contact
NIH OER Webmaster FBOWebmaster@OD.NIH.GOV
More from National Institutes of Health
Validation Center for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U54 Clinical Trials Not Allowed)
Logistics Center for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U24 Clinical Trials Not Allowed)
Development and Testing of a Multi-use Frameworks Playbook for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U01 Clinical Trial Not Allowed)
PRIMED-AI: Data-to-Model Academic-Industrial Partnerships (D2M-AIP) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (UG3/UH3 Clinical Trial Optional)
Model-to-Clinic (M2C) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (UG3/UH3, Clinical Trial Optional)
What to do next
Epigenetic Approaches in Cancer Epidemiology is closed; use the parent program and agency catalog for the next funding cycle.
- Parent CFDA 93.393 may publish future NOFOs under the same assistance listing. Open program
- Cancer Research Grants indexes 94 Grants.gov listings in this extract. Program profile
- National Institutes of Health lists 12,419 other indexed opportunities on PlainGrants. Agency catalog
Opportunity deadlines and eligibility change on Grants.gov; PlainGrants mirrors the extract and is not the submission system.
Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.
Read our methodology - how this data is sourced, computed, and verified.
| Publisher | PlainGrants |
| Sources | the SAM.gov Assistance Listings and Grants.gov |